. 2024 Jul 26;13(7):3783–3797. doi: 10.21037/tcr-24-747

Table 2. Summary of PFS and OS rate.

Author, year	Outcomes	Intervention 1			Intervention 2			RR (95% CI)
Author, year	Outcomes	Regimen	Rate, %	Total patients	Regimen	Rate, %	Total patients	RR (95% CI)
NCT00481247 (18)	5-year PFS rate	DAS 100 mg	88.80	259	IM 400 mg	89.23	260	1.00 (0.94–1.06)
Li, 2021 (22)	3-year PFS rate	NIL 300–400 mg	87.18	39	IM 400 mg	66.64	39	1.31 (1.02–1.68)
Jabbour, 2014 (19)	3-year PFS rate	DAS 100 mg	91.11	259	IM 400 mg	90.77	260	1.00 (0.95–1.06)
Kantarjian, 2012 (20)	2-year PFS rate	DAS 100 mg	93.82	259	IM 400 mg	91.92	260	1.02 (0.98–1.05)^a
Cortes, 2020 (25)	2-year PFS rate	DAS 100 mg	95.98	174	IM 400 mg	95.35	86	1.02 (0.98–1.05)^a
Brümmendorf, 2022 (16)	5-year OS rate	BOS 400 mg	94.31	246	IM 400 mg	94.61	241	1.00 (0.95–1.04)
NCT00481247 (18)	5-year OS rate	DAS 100 mg	90.73	259	IM 400 mg	89.61	260	1.01 (0.96–1.07)
Li, 2021 (22)	3-year OS rate	NIL 300–400 mg	92.31	39	IM 400 mg	79.49	39	1.16 (0.97–1.40)
Jabbour, 2014 (19)	3-year OS rate	DAS 100 mg	93.82	259	IM 400 mg	93.08	260	1.01 (0.96–1.05)
Kantarjian, 2012 (20)	2-year OS rate	DAS 100 mg	95.37	259	IM 400 mg	95.38	260	1.00 (0.97–1.03)^a
Cortes, 2020 (25)	2-year OS rate	DAS 100 mg	97.70	174	IM 400 mg	96.51	86	1.00 (0.97–1.03)^a

^a, RR reflects the pooled effect size through the meta-analysis. PFS, progression-free survival; OS, overall survival; RR, risk ratios; IM, imatinib; DAS, dasatinib; NIL, nilotinib; BOS, bosutinib.